Investigation Overview
Company
Security
NASDAQ: ADMA
Summary
August 17, 2016 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of ADMA Biologics Inc (NASDAQ:ADMA) was announced over potential breaches of fiduciary duties by certain officers and directors at ADMA Biologics.
The investigation by a law firm concerns whether certain ADMA Biologics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
ADMA Biologics Inc reported that its annual Total Revenue rose from $53.07 million in 2013 to $7.18 million in 2015 and that its Net Loss increased from $15.53 million in 2013 to $17.97 million in 2015.